Back to Search
Start Over
Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R-CHOP chemotherapy.
- Source :
-
Scientific reports [Sci Rep] 2024 May 16; Vol. 14 (1), pp. 11229. Date of Electronic Publication: 2024 May 16. - Publication Year :
- 2024
-
Abstract
- Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma, for which cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab(R-CHOP) is one of the standard regimens. Given that R-CHOP is highly emetogenic, chemotherapy-induced nausea and vomiting (CINV) prevention is clinically important. However, there is a paucity of studies focusing on these patients. This study aimed to ascertain the effectiveness of an oral fixed-dose combination of netupitant and palonosetron (NEPA) in preventing CINV in patients with DLBCL undergoing first-line R-CHOP chemotherapy. Seventy patients were enrolled in this single-center prospective non-comparative study conducted between November 2020 and May 2023 in South Korea. NEPA was administered 1 h prior to chemotherapy initiation on day 1. The primary endpoint of the study was the complete response rate (no emesis, and no rescue medication) during the acute, delayed, and overall phases, which were assessed over a period of 120 h post-chemotherapy. The complete response rates for NEPA were 90.0% [95% CI 80.5, 95.9] for the acute phase, 85.7% [95% CI 75.3, 92.9] for the delayed phase, and 84.3% [95% CI 73.6, 91.9] for the overall phase, with no-emesis rates (acute: 97.1% [95% CI 97.1, 99.7], delayed: 95.7% [95% CI 88.0, 99.1], overall: 92.9% [95% CI 84.1, 97.6]). NEPA was well tolerated with no severe treatment-emergent adverse events. NEPA exhibited substantial efficacy in mitigating CINV in DLBCL patients undergoing R-CHOP chemotherapy, demonstrating high CR and no-emesis rates, and favorable safety profiles.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Male
Female
Middle Aged
Aged
Adult
Prospective Studies
Pyridines adverse effects
Pyridines administration & dosage
Pyridines therapeutic use
Treatment Outcome
Drug Combinations
Isoquinolines
Quinuclidines
Lymphoma, Large B-Cell, Diffuse drug therapy
Antineoplastic Combined Chemotherapy Protocols adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Doxorubicin adverse effects
Doxorubicin administration & dosage
Cyclophosphamide adverse effects
Cyclophosphamide therapeutic use
Cyclophosphamide administration & dosage
Vincristine adverse effects
Vincristine therapeutic use
Vincristine administration & dosage
Nausea prevention & control
Nausea chemically induced
Vomiting prevention & control
Vomiting chemically induced
Rituximab adverse effects
Rituximab therapeutic use
Rituximab administration & dosage
Prednisone adverse effects
Prednisone administration & dosage
Prednisone therapeutic use
Palonosetron therapeutic use
Palonosetron administration & dosage
Antiemetics therapeutic use
Antiemetics administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 2045-2322
- Volume :
- 14
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Scientific reports
- Publication Type :
- Academic Journal
- Accession number :
- 38755279
- Full Text :
- https://doi.org/10.1038/s41598-024-62057-4